TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
AUTL

Autolus Therapeutics plc

Healthcare · Biotechnology · listed since 2018

1.20$ -1.7% vs. previous close Closing price · As of: Nov 13, 2026
🔔 Watch stock
Add to watchlist

Share this page

LinkedIn WhatsApp Email

Assessment

Our Rating

A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.

Substance risk

We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.

Why this colour

Red instead of yellow since the update of 11/14/2026: equity ($27.4 million as of 9/30/2026) is smaller than the net loss of a single quarter ($55.1 million in the third quarter), and even before interest the business lost $146.9 million in the first nine months of 2026, with $23.0 million of interest expense on top, while a first-lien creditor requires minimum liquidity and minimum revenue. On the other side stand $248.4 million of liquid funds (runway including the second loan tranche into Q2 2028 on the company's own statement), growing revenue and a 57 percent gross margin; the quarterly report explicitly reports no going concern doubt. This is a judgement on the company, not on the share price or timing.

What the thesis turns on

Assessment: Opportunities & Risks

Autolus has taken the step from trial to market: its own cancer therapy approved, manufactured and sold — $113.1 million of product revenue in nine months of 2026 and a 57 percent gross margin in the third quarter. The balance sheet, however, shows who has first call on that revenue: $293.3 million of royalty liabilities owed to Blackstone and BioNTech at an imputed rate of about 15.80 percent, plus a first-lien secured facility from Perceptive since July 30, 2026. Of $1,585.6 million paid in, only $27.4 million of equity remained as of September 30, 2026, while cash stands at $248.4 million; including the undrawn second loan tranche, resources last into Q2 2028 on the company's own arithmetic. Not investment advice.

Market entry & revenue

AUCATZYL has been approved in the United States since November 8, 2024 and is selling: $113.1 million of product revenue in the first nine months of 2026, more than in all of 2025; $41.2 million in the third quarter, 95 percent more than a year earlier. The step from trial to market has demonstrably been taken.

Cost of sales & margin

In fiscal 2025 manufacturing cost $96.4 million against $75.4 million of revenue — on average, every treatment was subsidized. In the third quarter of 2026, $17.9 million of cost of sales stood against $41.2 million of revenue; the company reports a 57 percent gross margin after 55 percent in the second quarter. That is a central operating advance of the past twelve months.

Capital structure & ranking

As of 9/30/2026 the balance sheet carries $293.3 million of royalty and milestone liabilities (Blackstone $248.2 million, BioNTech $45.1 million) at an imputed rate of about 15.80 percent; in the first nine months of 2026, $35.3 million of imputed interest accrued while $8.1 million was paid. Since 7/30/2026 Perceptive has also held a first-priority security interest in substantially all assets, with minimum liquidity and minimum revenue covenants. Shareholders come last in this order.

Equity & loss history

Of $1,585.6 million of paid-in capital, $27.4 million of equity remained as of 9/30/2026; at the end of 2025 it was $178.1 million (−85 percent in nine months). That is less than the third-quarter net loss ($55.1 million). The accumulated deficit reached $1,552.6 million; by its own account the company has incurred recurring losses since it was founded in 2014.

Sales momentum & guidance

The guidance raised on 11/10/2026 — at least $150 million — requires at least $36.9 million in the fourth quarter after $113.1 million in nine months, less than the third quarter's $41.2 million, which itself was below the second ($45.7 million). That may be caution for a therapy billed per patient, but it does not assume an unbroken steep curve. The EU market including Germany remains on hold despite approval in July 2025.

Cash runway

As of 9/30/2026 there was $245.4 million of cash and $3.0 million of marketable securities, and $25 million from the second Perceptive tranche can be drawn until 1/30/2027. At an operating cash outflow of $108.9 million over nine months that equals roughly seven and a half quarters on paper, or roughly six to seven after the contractual minimum liquidity; the company itself states a runway "into Q2 2028" and explicitly reports no going concern doubt in its quarterly report.

Worth Noting

AUTL reached our research list through the event sweep of new SEC filings: the Form 8-K dated 8/3/2026 on a secured financing of up to $250 million and the quarterly report for the period ended 6/30/2026 filed eight days later. Updated on 11/14/2026 with the quarterly report for the period ended 9/30/2026 and the earnings release of 11/10/2026; no verifiable call transcript was available.

Risk of confusion over filer status: Autolus is a British company that reported on Form 20-F through fiscal 2022 (2023 quarterly updates initially on Form 6-K) and has voluntarily filed regular 10-Q reports since the third quarter of 2023 and 10-K and 8-K reports since fiscal 2023 — legally as a foreign private issuer. That status ends on 1/1/2027. The evidence in this analysis therefore comes from 10-K/10-Q and 8-K filings, not from 20-F/6-K.

Risk of confusion over the company name: market data sets still carry the former name "Autolus Therapeutics Ltd". According to the 2025 annual report, the company re-registered as a public limited company and was renamed "Autolus Therapeutics plc" on June 18, 2018 (CIK 0001730463).

Valuation figures as of fixed dates: market capitalization about $352 million at $1.32 per share (close on 11/10/2026); at first publication about $590.9 million at $2.22 (close on 8/13/2026). Both are point-in-time anchors, not forecasts.

Stock Watch

This analysis is as of November 14, 2026. Stock Watch will tell you what's changed at AUTL since then.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 1.20 $ to 2.50 $ · Last price: 1.20 $ (As of: November 13, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 0.3$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 266m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 38.7%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. 2.3

Performance

Perf. 1M ?Price performance over the last month. 47.00%
Perf. 3M ?Price performance over the last 3 months. 29.80%
Perf. 6M ?Price performance over the last 6 months. 55.20%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). 11.56%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -4.7%
Perf. 1Y ?Price performance over the last 12 months. -8.59%
Perf. 3Y ?Price performance over the last 3 years. -68.03%
Perf. 5Y ?Price performance over the last 5 years. -83.04%
Perf. Since Inception ?Price performance since the first available trading day (06/22/2018) — with a complete history, that is since the IPO. -95.32%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 1.60$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 1.70$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 1.70$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 25.2
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 59.2%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 72.4%

Calculated from the price history · as of 11/14/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. –
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 0.0
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 2.7
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. 2.3
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. 0.03
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. –

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. -74.6%
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. -6,570.8%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. -238.6%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -29.6%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). -25.4%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 30.2%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.1
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. warning zone -3.14
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 3 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 83,655.20%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 646.68%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. -52.48%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. 26.90%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. B (56 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Biotechnology

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
Autolus Therapeutics plc AUTL 0.3 – 0.0 -74.6 -6,570.8 646.7 -8.6
Vertex Pharmaceuticals Inc VRTX 136.2 32.1 27.5 54.8 38.1 9.6 24.0
Regeneron Pharmaceuticals Inc REGN 99.3 24.1 14.1 46.7 20.7 1.0 38.2
Moderna Inc MRNA 88.6 – 4.6 -66.0 -131.1 -39.2 794.9
argenx NV ARGX 59.7 36.7 27.6 59.8 32.0 89.6 7.7
BeiGene, Ltd. ONC 47.1 74.4 29.5 89.4 19.1 40.2 10.2
Royalty Pharma Plc RPRX 38.2 37.5 24.0 99.8 100.3 5.1 78.4
Revolution Medicines Inc RVMD 35.8 – -9.7 -174,708.6 0.0 -100.0 167.6
Genmab AS GMAB 32.0 40.4 28.6 92.7 35.2 -82.7 69.9
Median of companies shown 47.1 37.1 24.0 54.8 20.7 5.1 38.2

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year $M

Revenue Operating income Net income

2016 · Revenue: 1 $M 2016 · Operating income: -14 $M 2016 · Net income: -13 $M 2017 · Revenue: 2 $M 2017 · Operating income: -23 $M 2017 · Net income: -20 $M 2018 · Revenue: 1 $M 2018 · Operating income: -58 $M 2018 · Net income: -31 $M 2019 · Revenue: 3 $M 2019 · Operating income: -248 $M 2019 · Net income: -124 $M 2020 · Revenue: 2 $M 2020 · Operating income: -303 $M 2020 · Net income: -142 $M 2021 · Revenue: 2 $M 2021 · Operating income: -140 $M 2021 · Net income: -142 $M 2022 · Revenue: 6 $M 2022 · Operating income: -143 $M 2022 · Net income: -149 $M 2023 · Revenue: 2 $M 2023 · Operating income: -180 $M 2023 · Net income: -208 $M 2024 · Revenue: 10 $M 2024 · Operating income: -241 $M 2024 · Net income: -221 $M 2025 · Revenue: 76 $M 2025 · Operating income: -281 $M 2025 · Net income: -288 $M
2016201720182019202020212022202320242025
Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 1 -14 -13 -0.91 -10 31 34
2017 2 -23 -20 -1.43 -16 143 149
2018 1 -58 -31 -0.99 -26 205 218
2019 3 -248 -124 -2.88 -101 255 304
2020 2 -303 -142 -2.76 -118 210 294
2021 2 -140 -142 -1.97 -118 313 406
2022 6 -143 -149 -1.57 -112 299 490
2023 2 -180 -208 -1.20 -146 111 375
2024 10 -241 -221 -0.86 -206 427 783
2025 76 -281 -288 -1.08 -284 178 589

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q2 · 0.0 $M Q2 2024: Q3 · 0.0 $M Q3 2024: Q4 · 0.0 $M Q4 2025: Q1 · 9.0 $M Q1 2025: Q2 · 20.9 $M Q2 2025: Q3 · 21.2 $M Q3 2025: Q4 · 24.3 $M Q4 2026: Q1 · 26.2 $M Q1 2026: Q2 · 45.7 $M Q2 2026: Q3 · 41.2 $M Q3

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q2 -0.22 15.40 0 – – -51 -52
2024: Q3 -0.31 -19.20 0 -100.00 – -77 -86
2024: Q4 -0.09 80.00 0 -98.40 -95,193.10 -38 -62
2025: Q1 -0.26 -8.30 9 -11.00 -781.10 -76 -84
2025: Q2 -0.18 18.20 21 – -229.00 -73 -80
2025: Q3 -0.30 3.20 21 – -373.30 -68 -83
2025: Q4 -0.34 -277.80 24 83,534.20 -371.90 -67 -91
2026: Q1 -0.27 -3.80 26 191.90 -273.10 -65 -68
2026: Q2 -0.15 16.70 46 118.40 -85.60 -25 -26
2026: Q3 -0.21 30.00 41 94.30 -133.70 -19 -20

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 5 of our scanner strategies — each hit links to the scanner.

Growth

Quality & Balance Sheet

Research

Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Strong Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings 9
Price Target (average) 8.75$
Distance to price 629.2% The price target sits 629.2% above the current price.

Distribution of Recommendations

Strong Buy 8
Buy 1
Hold 0
Sell 0
Strong Sell 0

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -0.80 -0.94 – -0.61 150 26.3% 8
12/31/2027 -0.63 -0.94 – -0.31 192 20.5% 8

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Valuation

What is priced in?

Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.

A simplified model calculation — not a forecast and not a recommendation.

AI classification

AI Rating

Uses AI

Autolus setzt künstliche Intelligenz nach eigener Darstellung bereits in Teilen von Forschung und Entwicklung ein — unter anderem bei der Identifikation möglicher Wirkstoffkandidaten — und will sie auf Wirkstoffsuche, Entwicklung, Vermarktung und Verwaltung ausweiten; verkauft wird jedoch ausschließlich die Zelltherapie AUCATZYL, ein eigener KI-Umsatz oder ein KI-Segment wird in Geschäfts- und Quartalsbericht nirgends ausgewiesen. Fortschreibung 11. November 2026: Der Quartalsbericht zum 30. September 2026 (10-Q vom 10. November 2026) und die Ergebnismitteilung (8-K, Anlage 99.1) nennen künstliche Intelligenz nicht; verkauft wird weiterhin ausschließlich AUCATZYL, ein KI-Umsatz oder KI-Segment wird nicht ausgewiesen. Die Einstufung „nutzt“ bleibt auf Basis des Geschäftsberichts 2025 bestehen.

View the full file — quotes, sources, reviewed filings
„We currently integrate artificial intelligence (“AI”) in certain of our research and development activities, including identification of potential product candidates, and are seeking to further integrate AI throughout our business."

Wir setzen künstliche Intelligenz („KI“) derzeit in bestimmten unserer Forschungs- und Entwicklungstätigkeiten ein, einschließlich der Identifikation möglicher Produktkandidaten, und streben an, KI in unserem gesamten Geschäft weiter zu verankern.

10-K · 2026-03-27 · View SEC filing

„We are exploring additional opportunities to incorporate AI into our processes for drug discovery, drug development, drug commercialization, and in connection with our general & administrative functions."

Wir prüfen weitere Möglichkeiten, KI in unsere Abläufe für Wirkstoffsuche, Arzneimittelentwicklung und Vermarktung sowie im Zusammenhang mit unseren allgemeinen Verwaltungsfunktionen einzubinden.

10-K · 2026-03-27 · View SEC filing

„We may also face increased competition from other companies that are using AI, some of whom may develop more effective methods than we and any of our business partners have, which could have a material adverse effect on our business, results of operations, or financial condition."

Wir könnten zudem verstärktem Wettbewerb durch andere Unternehmen ausgesetzt sein, die KI einsetzen und von denen einige wirksamere Methoden entwickeln könnten als wir und unsere Geschäftspartner, was sich wesentlich nachteilig auf unser Geschäft, unsere Ertragslage oder unsere Finanzlage auswirken könnte.

10-K · 2026-03-27 · View SEC filing

Filings Reviewed: 10-Q 2026-11-10 · 10-Q 2026-08-11 · 10-Q 2026-05-14 · 10-K 2026-03-27 · 10-Q 2025-11-12 · 10-Q 2025-08-12 · 10-K 2025-03-20

Rated on November 11, 2026 · How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

4 of 10 Weak growth
  • Revenue grows by more than 15% a year over three years 130.2%
  • More than 10% revenue growth is expected for the coming year -52.5%
  • Share count grows by less than 3% a year 41.0%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 235.5%
  • Gross margin at 40% or higher and without meaningful erosion -27.8%
  • Goodwill from acquisitions does not grow faster than revenue 0.0%
  • Net debt below twice EBITDA failed
  • Operating cash flow covers the profits of the last three years 82 m
  • Return on capital at 15% or higher, or up versus two years ago -54.6%
  • Insiders hold at least 10% or are net buyers 18.1%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

3/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% 58.3%
  • Exp. sales growth 3Y > 5% 59.6%
  • EBIT growth 10Y > 5% –
  • Exp. EBIT growth 3Y > 5% 59.6%
  • Net debt < 4x EBIT –
  • EBIT positive, 10Y straight 0
  • Max. EBIT decline < 50% –
  • Return on equity > 15% -182.0%
  • ROCE > 15% -54.6%
  • Expected return > 10% -95.8%

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

Insiders

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

Insider Transactions
Date Person Role Type Shares Price Value
Sep 2, 2026 Piccina Cintia U.S. CCO & Country Gen Manager Sell 6,713 2.34 15,682
Sep 1, 2026 Piccina Cintia U.S. CCO & Country Gen Manager Other 20,000 2.35 47,000

View all insider transactions →

The company

About the Company

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Employees
752
Headquarters
London, United Kingdom
Address
The Mediaworks, W12 7FP London, United Kingdom
Phone
44 20 3829 6230
IPO Date
06/22/2018
ISIN
US05280R1005

Management

Management
Name Title Birth Year
Christian Martin Itin Ph.D. CEO & Director 1964
Martin Pule M.D., MBBS Founder, Senior VP & Chief Scientific Officer 1972
Robert F. Dolski Senior VP & CFO 1971
Christopher Vann Senior VP & COO 1965
Patrick McIlvenny Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer 1980
Miranda Neville Senior VP & Chief Technology Officer 1975
Alex Driggs Senior VP of Legal Affairs & General Counsel and Secretary 1976
Alexander Swan Senior VP & Chief Human Resources Officer 1965
Christopher Williams Ph.D. Senior VP & Chief Business Development Officer 1980
Matthias Will M.D. Senior VP & Chief Development Officer 1973

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Filings

Company Filings (8-K)

An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).

  • 11/10/2026 Autolus Therapeutics plc (AUTL): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?